Roger Green and Ali Spiro of RG+A present on how to “win” the messaging battle at PMRC (Pharma Market Research Conference) on February 6, 2020.

RG+A a leading innovative life sciences market research and strategy agency is excited to be sponsoring the 2019 HITLAB World Cup: Women’s Health Tech Challenge.

In a recent article for Quirk’s Magazine, Roger Green, President and CEO at RG+A, reports on findings from a survey of 1,100 physicians to test the precision of allocation versus patient simulation.

Complex findings require many moving pieces to be held in the mind at once to grasp the full picture. In our DPS® studies, for instance, RG+A determines not only what will happen, but also where, when, and why. Answering these questions provides a comprehensive view of the overall market space and the decisions physicians make that create the prescribing environment.

Welcome to Part 3 of our series on data visualization! Information overload happens when data gets in its own way. If information is not easily grasped with the implications understood, it will be ignored or potentially misinterpreted. The result is slow, poor, or uninformed decision making.

In Part 2 of RG+A’s data visualization series, we discuss how to avoid building poor visualizations by ensuring charts and graphs are true to the data.

Though it is painful to admit, we know that our projects are not the only thing our clients have to manage. From emails to dashboards and data-driven business insights, the amount of data that exists has increased (exponentially over time), and so has the amount of data that everyone must manage daily.

What happens if we are wrong? It is a critical question in risk assessment. A wrong decision has implications, sometimes small and inconsequential, sometimes large and disastrous. A wise decision maker always considers the implications of making the wrong choice and factors that into the final decision.

When there is an undefined or underdeveloped vision before research is designed and fielded, optimal success cannot be achieved. Final research results must produce a clear, quantifiable benefit, or the money and time spent on the research was wasted.

Healthcare products companies of all sizes flourish or fade based on their ability to build robust portfolios by acquiring high-value assets and culling low-level ones. In 2015, there were 468 announced deals involving therapeutic drug assets, devices, diagnostics and insurance companies, according to data from Thomson Reuters, representing a 10% increase over 2014 and a 90% increase over 2012. This extends a trend of an increasing number of deals, beginning in 2013 after a sustained decrease during the economic downturn around 2008.

As provider reimbursement systems move toward compensation for success rather than service, some health plans are encouraging manufacturers to take on some of the market risks for new agents in exchange for preferential management. As pharmaceutical companies seek to develop new and successful market access strategies, they should proactively approach certain types of plans with offers of performance-based contracts.

PAs can impose significant limits on market access and uptake for pharmaceutical products, and their application should not be oversimplified. Over the past 12 years, most of my payer research has included an element exploring and analyzing the PAs that were likely to be imposed on a new agent to market or an older agent […]

Prescribing simulation was born 20 years ago in the aftermath of a methods debate in which supporters of two flawed methodologies focused more on attacking the other than improving their own. Takeaways For Marketing Researchers: Don’t settle for the “least-bad” method. You may need to get creative to develop a better approach, but the payoff […]

At a Spring PMRG meeting, the highest rated presentation, given before a standing-room-only audience, debuted a new mode of marketing research called patient simulation. The presentation focused on how this method provided more reliable data than traditional allocation and estimation methods and improved response and interview completion rates dramatically. If you were at PMRG CONNECT 2016 […]

Welcome back to my three-part series on physician treatment behavior. If you missed the first installment, you can find it here. In this second installment, I will be discussing the use of patient chart pulls as a way to understand both current and future physician prescribing. Patient chart pulls offer significant advantages to allocation studies, […]